GW572016 For Treatment Of Refractory Metastatic Breast Cancer
This study was designed to determine the efficacy of an oral dual kinase inhibitor for the treatment of metastatic breast cancer tumors that are known to overexpress ErbB2 in a refractory patient population.
Neoplasms, Breast
DRUG: GW572016
Tumor response rate
clinical benefit rate time to progression 4 and 6 month progression free survival overall survival
This study was designed to determine the efficacy of an oral dual kinase inhibitor for the treatment of metastatic breast cancer tumors that are known to overexpress ErbB2 in a refractory patient population.